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medical and prescription claims collected over a 4-year study period (January 1, 
2001–December 31, 2004) from more than 300,000 employees. Data from employees 
with and without (controls) functional dyspepsia were compared using 2-part regres-
sion techniques. Outcome measures included direct and indirect costs paid by the 
employer, absenteeism, direct costs by the place of service where care was performed, 
and objectively measured productivity output. RESULTS: Employees with functional 
dyspepsia (N = 1669) had greater average annual direct medical and prescription drug 
costs and indirect costs (due to sick leave, short- and long-term disability absences) 
than controls (N = 274,206). Compared with controls, the functional dyspepsia 
employees incurred health beneﬁt costs that were $5,138 greater and had greater costs 
for each place of service (all P < 0.0001). The employees with functional dyspepsia 
had an additional 0.83 absence days per year and produced 12% fewer units per hour 
than controls (both P < 0.05). CONCLUSIONS: Employees with functional dyspepsia 
have greater costs at all places of service and lower productivity than employees 
without functional dyspepsia.
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OBJECTIVES: The aim of this study was to estimate the annual societal disease 
burden of irritable bowel syndrome (IBS) in Korea for the year of 2008. METHODS: 
The claim data with IBS were extracted from the Health Insurance Review & Assess-
ment Service database in 2008 of Korea. After deﬁnition of patient with specialists, 
the prevalence and medical costs were calculated. The number of outpatient visits and 
length of hospital stay also were calculated to estimate transportation cost and pro-
ductivity loss. RESULTS: The annual national patients with IBS were estimated to 
1.30 million with 753,688 (57.79%) for female. The results showed that the 
crude prevalence of IBS was 2.68% (95%CI: 2.66%-2.71%, 2.25% for male and 
3.12% for female) in 2008. The total cost due to IBS was 14.9 billion won (1$ = 
1047.30 won, 2008) including 348 million won for direct medical cost (2.33%), 88 
million won for nonmedical cost (transportation costs), and 14.5 billion won for lost 
work due to illness. CONCLUSIONS: The disease burden of IBS appears to be high 
because of the high morbidity although not a signiﬁcant cause of death. The result is 
likely to underestimate due to using claim data and strict deﬁnition of patient. 
However, this data might be useful and necessary to support evidence based decision 
making for IBS.
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OBJECTIVES: To compare direct and indirect costs between HCV patients on 
pegylated interferon with ribavirin (PEG-RBV), untreated HCV, and non-HCV con-
trols. METHODS: We identiﬁed three cohorts using the MarketScan Commercial 
Claims and Encounters Database® from 2002–2007: HCV patients on PEG-RBV, 
untreated HCV, and non-HCV controls. We used propensity scores to match treated 
to untreated (1:1), and HCV to non-HCV patients (1:3). We compared direct costs 
and utilization across the cohorts. We performed subset analysis using the MarketScan 
Health and Productivity Management Database® to evaluate absenteeism and short-
term disability costs. RESULTS: We identiﬁed 10,001 PEG-RBV patients. Compared 
to untreated patients, treated patients had higher total medical costs ($28,547 vs. 
$21,752; p < 0.001) outpatient pharmacy costs ($17,419 vs. $2,900; p < 0.001) and 
outpatient physician visit costs ($894 vs. $787; p < 0.001), but lower inpatient costs 
($3,942 vs. $9,543; p < 0.001) and ER costs ($366 vs. $505; p < 0.001). Treated 
patients had similar absenteeism rates (93% vs. 88%; p = 0.27), higher short-term 
disability rates (33% vs. 30%;p < 0.001) and higher indirect costs ($11,528 vs. 
$9,316; p < 0.05). Non-HCV controls had signiﬁcantly lower costs in all categories 
compared to patients with HCV. Total costs among matched non-HCV costs were 
$15,932, outpatient pharmacy costs were $1,796, outpatient physician visit costs were 
$429, inpatient costs were $2,181, and ER costs were $184; indirect costs were 
$7,654. After adjusting for demographic and clinical characteristics, including HIV 
and cirrhosis, differences remained signiﬁcant but diminished. CONCLUSIONS: HCV 
patients engender a higher economic burden compared to non-HCV controls. Treated 
patients cost more than untreated patients; the cost differential is primarily driven by 
higher outpatient pharmacy costs. Indirect cost differences are driven by greater 
absenteeism duration and greater short term disability use and duration. These data 
provide insight into the economic burden of HCV and its treatment, and may be 
employed in future health economic analyses evaluating existing and emerging 
therapies.
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OBJECTIVES: To document variations in resource utilization and costs by disease 
severity, sustained viral response (SVR), and genotype in a European population with 
chronic hepatitis C virus (C-HCV). METHODS: Patient charts from the UK, France, 
Germany, Spain, and Italy were retrospectively reviewed. Inclusion criteria were: 
C-HCV diagnosis within past 5 years; age ≥18 years; no diagnoses of hepatitis B or 
HIV/AIDS; ≥1 year follow-up post-diagnosis; no clinical trial participation. All-cause 
utilization and costs (2009 3) for hospitalizations, emergency room (ER) and ofﬁce 
visits, and specialty referrals were aggregated within patients over 1 year post-diag-
nosis. C-HCV severity was assessed via Metavir score. Among patients receiving 
C-HCV-directed pharmacotherapy, SVR was deﬁned by viral RNA < 10 IU/mL at ≥6 
months post-treatment. Utilization and cost differences across clinical factors were 
assessed with multivariate modeling. RESULTS: In total, 1016 patients were identi-
ﬁed. Overall, 23% of severe patients were hospitalized versus 2.5% of mild. Hospi-
talization was 5 times more likely in severe C-HCV compared to mild (odds ratio 
[OR] = 5.39; P = 0.008), while the hospitalization rate, measured by Poisson incidence 
rate ratio (IRR), was 4 times higher (IRR = 3.98; P = 0.010). Hospital costs were 
31380 higher in severe versus mild disease (P = 0.001). Hospitalization risk in SVR 
attainers was less than half that of non-attainers (OR = 0.22; P < 0.0001). ER, ofﬁce, 
and specialist visit rates were signiﬁcantly lower among SVR attainers. Genotype had 
little effect on utilization, but genotype 1 was associated with slightly lower (390 per 
patient; P < 0.0001) hospital costs versus genotypes ≥2. CONCLUSIONS: Disease 
severity and SVR are important predictors of C-HCV costs. Awareness of these factors 
by public health systems, which bear the high cost burden of C-HCV, may help 
promote strategies for earlier disease detection and increased treatment initiation 
before progression occurs, as well as formulary access for more convenient therapies 
that increase treatment persistence and thereby SVR rates.
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OBJECTIVES: Assess patterns of utilization and costs of twice daily 24 mcg dosing 
of lubiprostone in a large managed care population. METHODS: Patients included 
Humana members 18 years and older with medical claims for chronic constipation 
(CC) and/or irritable bowel syndrome (IBS) between April 1, 2006 and April 30, 2008. 
The index date was the ﬁrst diagnosis of CC or IBS. Patients had at least 180-days of 
continuous enrollment pre-index and at least 30-days post-index. Users and non-users 
were compared. Users were compared pre- and post-lubiprostone initiation. RESULTS: 
A total of 92,804 patients with a diagnosis of CC or IBS were identiﬁed during the 
study period; 1873 ﬁlled at least one 30-day prescription for lubiprostone. Seventy-ﬁve 
percent of users were female. Lubiprostone users were younger than non-users (61.6 
vs. 66.2 yrs old) and more likely to be co-prescribed opiates (35.5 vs. 29.4%), anti-
histamines (14.8 vs. 9.5%) and tricyclic antidepressants (8.1 vs. 4.7%), all statistically 
signiﬁcant. Common co-morbidities in lubiprostone users were back problems 
(23.6%) and abdominal pain (21.9%). A total of 1605 users had both 6-months pre- 
and post-lubiprostone initiation data. A total of 42.2% of these patients ﬁlled more 
than one 30-day lubiprostone prescription; 6.42% ﬁlled 6 or more. Usage of other 
prescription laxatives decreased by 4.6% (p < 0.05) subsequent to lubiprostone initia-
tion. Monthly health care costs per utilizing member increased by $67.10 (p < 0.0001). 
Pharmacy costs rose by $71.73 (p < 0.0001) and ER costs decreased by $8.12 (p < 
0.05). Pre-post changes in outpatient and inpatient costs were not signiﬁcant. Monthly 
inpatient and ER visits for these 1605 members decreased by 0.31 and 0.08 per utiliz-
ing member respectively (p < 0.05) in the 6-months after starting lubiprostone. 
Changes in outpatient visits were not signiﬁcant. CONCLUSIONS: Lubiprostone 
users were younger females who were co-prescribed opiates and had back problems. 
Higher health care costs were offset by a decrease in ER costs.
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Hepatitis C affects approximately 180 million people worldwide and is one of the 
main causes of chronic liver disease. HCV infection progresses to chronicity in approx-
imately 80% of infected individuals, from whom up to 20% can develop cirrhosis 
over 20 years, thus presenting high risk of complications related to hepatic insufﬁ-
ciency and/or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs 
and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated 
